By Colin Kellaher
Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.
Regeneron on Thursday said it will make a $100 million up-front payment to Mammoth, including a $95 million equity investment in the biotechnology company.
Tarrytown, N.Y., biotechnology company Regeneron said it will pair its delivery technologies with Mammoth's proprietary Crispr-based gene-editing platform to advance in-vivo programs in multiple tissue and cell types.
Regeneron said Mammoth will be eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, along with royalties on sales of all collaboration products.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
04-25-24 0804ET